U.S. markets open in 8 hours 17 minutes

Pieris Pharmaceuticals, Inc. (PIRS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
5.49-0.36 (-6.15%)
At close: 4:00PM EDT
Sign in to post a message.
  • E
    Edward m
    i remember owning NIO and all of us were begging for 6. It finally hit 6...then 60. we looked back at6 and laughed for wanting only 6. Maybe this stock will do the same.
  • A
    To find the recent prs 220 poster presentation....search by pasting the below:

    Development of PRS-220, a potential best-in-class, inhaled CTGF/CCN2 inhibitor for the treatment of IPF
  • M
    The reason I got so interested in Pieris 2 months ago at $3.4 per share, is I have never seen a biotech with such a small market cap (at the time under $200 million) have agreements with such large pharma. The agreements they have, companies with much larger market caps would love to have. I admit the potential payments are only potential but a) it appears they are already getting some of those payments per 10k, and b) you have to ask why are all of these companies lining up with Pieris. If it were just one or two companies I would not think much of it. I don't understand what is so special about their library of more than 100 billion different Anticalin proteins, but the 5 companies below do and apparently it is because they believe the proteins can be a candidate for any therapeutic target. Obviously high risk but this could be a seriously high reward.

    The 5 contracts listed below are agreements signed since Covid, There may be other these are the ones I know of.
    Collaboration with a) AstraZeneca : AstraZeneca has paid $45 million and committed to up to $2.1 billion in milestones to team with Pieris Pharmaceuticals. The agreement sets Pieris up to move respiratory candidate PRS-060 into the clinic on AstraZeneca’s dime and pull in milestones as it and other pipeline prospects advance.
    with b) Genentech : $20 million upfront up to $1.4B potential payment + royalties in milestones across multiple platforms
    with c) SeaGen: $13 million investment at 3.51 per share $1.2B potential payment + royalties
    with d) Boston Pharma : 10 million upfront potential $353M payment + royalties and undisclosed amount for manufacturing, yahoo board says this is not $800 million now I can't find any press release where this changed
    wtih e) Lilly - clinical trial collaboration and supply agreement to evaluate a combination of candidates in multiple types of solid tumoirs, including HER2-positive tumours. The clinical trial programme will evaluate the safety and efficacy of Pieris’ PRS-343, a 4-1BB/HER2 bispecific targeting HER2-positive tumours,
  • J
    Jose V
    Pieris Pharmaceuticals to Participate in Upcoming Investor Conferences
    September 09, 2021 8:00am EDT
    BOSTON, MA / ACCESSWIRE / September 9, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced that members of the management team will participate in the following upcoming investor conferences:

    H.C. Wainwright 23rd Annual Global Investment Conference
    Monday, September 13, 2021 at 7:00 AM EDT. A webcast of the Company's presentation will be available at this link.

    Cantor Global Healthcare Conference
    Thursday, September 30, 2021 at 12:00 PM EDT. A webcast of the Company's presentation will be available at this link.
  • C
    Ching bing dingo ling
    $1.4billion x4/5years= a lot of market cap
  • A
    My pick for a moon shot in 2022 is Pieris Pharmaceuticals (NASDAQ:PIRS). I opened up a tiny position in June, buying 200 shares at $3.50. If that seems kind of tentative, yes, yes it is. That's because Pieris has no profits, barely has revenue, and has no drugs on the market. As a matter of fact, we don't even have phase 2 data on any of its offerings yet. Pieris is a highly risky biotech.

    My family portfolio is filled with highly risky biotechs, and every year it seems like my worst performers are highly risky biotechs. But that's OK, because my positions are small, and a few winners can make a big difference. I have a few larger positions that are high-confidence -- mainly profitable biotechs, or companies on the verge of FDA approval. And then there's Pieris. I bought more shares in July, and more shares in August. And this week I added some more. But it's still a very small investment. My No. 1 stock, Shopify (NYSE:SHOP), is 67 times larger than my Pieris position.

    Nonetheless, I want to own Pieris because if the phase 2 trials are positive, the upside is far bigger than usual for a drug company. Pieris created and owns the rights to Anticalin drugs. These drugs are eight times smaller than monoclonal antibodies, a major class of pharmaceuticals. Why does that matter? Well, for instance, antibodies can't go into the lung. The molecules are too big.

    If you're fighting asthma, a drug that can access the lung is very helpful. Certainly
  • j
    Add a 1 before the stock price. Lots of potential for this company.
  • D
    ( PIRS) Pieris Pharmaceuticals Inc., buying out price Target = $20

    Potential Buyers - Swiss drug giant Roche or Genentech besides Pieris' has a number of big-name partnerships: Over the last several years, the biotech has inked deals with AstraZeneca (NASDAQ: AZN), Servier, Allergan, Sanofi (NYSE: SNY), Daiichi Sankyo and Roche itself, among others.
  • C
    Crusher 4 U
    Noticed 7% up in my portfolio and couldn't resist to lock in the profits this morning. Thanks guys...but as the author pumped this could touch 100's in 2022 which I have not seen
  • D
    Announced inhaled program PRS-220 for the treatment of IPF and was selected to receive a Bavarian government grant of approximately $17 million to evaluate the program for post-COVID pulmonary fibrosis

    Signed respiratory and ophthalmology agreement with Genentech with a $20 million upfront payment and more than $1.4 billion in potential additional milestone payments
    Tim Demuth, M.D., Ph.D., appointed Chief Medical Officer and Shane Olwill, Ph.D., promoted to Chief Development Officer
    Reiterated guidance for near-term and ongoing clinical studies
    June 30th ending cash balance in excess of $119M
  • Q
    Nice. They just added some LEAP with $10 strike
  • J
    Jose V
    Not a technical expert but the three months daily is looking great, any thoughts?
  • Q
    Still buying. 6 next
  • M
    It just keeps getting better and better everyday. Somebody knows something.
  • m
    Been researching PIRS. An experienced biotech investor. Don't understand the tons of potential from seeking alpha extensive review of early stage clinical trials (why in non US markets?) with no apparent follow up on those initial trials. Did they all fail to meet their end points? The science seems to be very promising, but I don't see any positive results. I look for paradigm changing companies and this seems to be one. BUT, no results yet after P-1's in 2013/2014 or P-2's later. That's a lot of time to digest the validity of the science. Any thoughts from informed non-bashers/pumpers would be appreciated.
  • z
    (http://Thetraderguide.com) is a must for any trader. Their watchlist which covers pre-market movers is one of the best researched in the industry. I don’t start trading without reading their daily email each morning!
  • m
    I am accumulating
  • J
    AstraZeneca or Roche should make a buyout offer before the daytraders get wind of this stock and pump it to $40.
  • S
    $5.70 nice
  • H
    Will this stock be like SAVA going up from $3 to almost $148 a month ago? Is it going to happen?